Abstract:Background: beta-Amyloid (A beta) fibrillation is critical for A beta deposition and cytotoxicity during the progression of Alzheimer's disease (AD). Consequently, anti-A beta monoclonal antibody drugs targeting A beta oligomers and aggregation are considered potential therapeutic strategies for AD treatment. Similar to the working mechanisms of anti-A beta monoclonal antibody drugs, our study identified osmundacetone (OAC), a small-molecule compound isolated from the traditional Chinese medicine Rhizoma Osmundae, as exerting anti-AD effects by targeting A beta. Purpose: This study sought to determine whether OAC influences the A beta burden in APP/PS1 mice and to identify potential regulatory mechanisms. Methods: Five-month-old APP/PS1 mice were injected intraperitoneally with OAC at a dose of 1 mg/kg for 12 weeks. The cognitive functions of the mice were assessed via the Morris water maze test and the open field test. Osmundacetone was analyzed via molecular docking, an isothermal dose-response fingerprint-cellular context thermal shift assay, a thioflavine T fluorescence assay, and an atomic force microscopy assay to analyze the effects of OAC on A beta fibrillation. Immunofluorescence, immunoblotting, and immunohistochemistry were used to assess A beta clearance, AD pathology, oxidative stress, and inflammatory responses. Results: The innovative biochemical and physical data illustrated that the ability of OAC to inhibit A beta fibrillation was accomplished by binding directly to A beta, which differed from the majority of previously reported natural polyphenols that modulate the A beta content and structure in an indirect manner. The inhibition of A beta fibrosis by OAC subsequently promoted A beta lysosomal degradation, resulting in a decreased A beta burden in APP/PS1 mice. Furthermore, OAC treatment inhibited oxidative damage by upregulating glutathione peroxidase expression and attenuated the production of inflammatory factors by downregulating nuclear factor-kB phosphorylation in APP/ PS1 mice. Conclusion: These findings demonstrate, for the first time, that OAC could reduce the brain A beta burden in APP/PS1 mice by inhibiting A beta fibrillation through direct binding to A beta and improve cognitive dysfunction by attenuating oxidative damage and neuroinflammation. These findings indicate that OAC may be a promising candidate for the treatment of AD.

Structural Characterization of Polysaccharide Purified from Amanita Caesarea and Its Pharmacological Basis for Application in Alzheimer's Disease: Endoplasmic Reticulum Stress

Mannose‐rich Exopolysaccharide from Agaricus Sinodeliciosus Var. Chaidam: Purification, Chemical Characterization, and Neuroprotective Activity

Structural characterization of polysaccharide purified from Hericium erinaceus fermented mycelium and its pharmacological basis for application in Alzheimer's disease: Oxidative stress related calcium homeostasis

Structural characterization of polysaccharide purified from<i> Hericium</i><i> erinaceus</i> fermented mycelium and its pharmacological basis for application in Alzheimer's disease: Oxidative stress related calcium homeostasis

Structural characterization of Hericium coralloides polysaccharide and its neuroprotective function in Alzheimer's disease

Polysaccharide from Polygala tenuifolia alleviates cognitive decline in Alzheimer's disease mice by alleviating Aβ damage and targeting the ERK pathway

Structure characterisation of polysaccharides purified from Boletus aereus Bull. and its improvement on AD-like behaviours via reliving neuroinflammation in APP/PS1 mice

Polysaccharide Krestin Prevents Alzheimer’s Disease-type Pathology and Cognitive Deficits by Enhancing Monocyte Amyloid-β Processing

Polysaccharides: Potential Bioactive Macromolecules for Alzheimer’s Disease

Pseudostellaria heterophylla polysaccharide mitigates Alzheimer's-like pathology via regulating the microbiota-gut-brain axis in 5 × FAD mice

A Polysaccharide from Polygonatum Sibiricum Attenuates Amyloid-Β-induced Neurotoxicity in PC12 Cells.

Astragalus polysaccharide alleviates cognitive impairment and β-amyloid accumulation in APP/PS1 mice via Nrf2 pathway

Extraction of Polysaccharides From Bletilla Striata Using a Modified Low-temperature Method and Evaluation of Their Efficacy Against Alzheimer’s Disease

Polysaccharides from Lycium Barbarum Ameliorate Amyloid Pathology and Cognitive Functions in APP/PS1 Transgenic Mice.

Armillariella tabescens-derived polysaccharides alleviated Ɒ-Gal-induced neuroinflammation and cognitive injury through enterocerebral axis and activation of keap-1/Nrf2 pathway

Characterization of lactic acid bacteria derived exopolysaccharides for use as a defined neuroprotective agent against amyloid beta1-42-induced apoptosis in SH-SY5Y cells

Modulation of the Aβ-Peptide-Aggregation Pathway by Active Compounds From Platycladus orientalis Seed Extract in Alzheimer's Disease Models

Ganoderic acid a alleviates Aβ25−35-induced HT22 cell apoptosis through the ERK/MAPK pathway: a system pharmacology and in vitro experimental validation

Effects of an Armillaria mellea Polysaccharide on Learning and Memory of D-Galactose-Induced Aging Mice

Osmundacetone Ameliorates Alzheimer's-like Pathologies by Inhibiting (3-Amyloid Fibrillation, Oxidative Damage and Neuroinflammation in APP/ PS1 Transgenic Mice

Modulation of the Aβ-Peptide-Aggregation Pathway by Active Compounds From Platycladus orientalis Seed Extract in Alzheimer’s Disease Models